Your browser doesn't support javascript.
loading
Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG.
Pyankov, Oleg V; Setoh, Yin Xiang; Bodnev, Sergey A; Edmonds, Judith H; Pyankova, Olga G; Pyankov, Stepan A; Pali, Gabor; Belford, Shane; Lu, Louis; La, Mylinh; Lovrecz, George; Volchkova, Valentina A; Chappell, Keith J; Watterson, Daniel; Marsh, Glenn; Young, Paul R; Agafonov, Alexander A; Farmer, Jillann F; Volchkov, Victor E; Suhrbier, Andreas; Khromykh, Alexander A.
  • Pyankov OV; State Center for Virology and Biotechnology Vector, Koltsovo, Russian Federation.
  • Setoh YX; Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Brisbane, QLD, Australia.
  • Bodnev SA; State Center for Virology and Biotechnology Vector, Koltsovo, Russian Federation.
  • Edmonds JH; Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Brisbane, QLD, Australia.
  • Pyankova OG; State Center for Virology and Biotechnology Vector, Koltsovo, Russian Federation.
  • Pyankov SA; State Center for Virology and Biotechnology Vector, Koltsovo, Russian Federation.
  • Pali G; Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Brisbane, QLD, Australia.
  • Belford S; Plasvacc Pty. Ltd., Kalbar, QLD, Australia.
  • Lu L; Bio Medical Manufacturing, Fermentation and Protein Production Facility, CSIRO, Clayton, VIC, Australia.
  • La M; Bio Medical Manufacturing, Fermentation and Protein Production Facility, CSIRO, Clayton, VIC, Australia.
  • Lovrecz G; Bio Medical Manufacturing, Fermentation and Protein Production Facility, CSIRO, Clayton, VIC, Australia.
  • Volchkova VA; Molecular Basis of Viral Pathogenicity, CIRI, INSERM, U1111-CNRS UMR5308, Université de Lyon, Université Claude Bernard Lyon 1, Ecole Normale Supérieure de Lyon, France.
  • Chappell KJ; Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Brisbane, QLD, Australia.
  • Watterson D; Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Brisbane, QLD, Australia.
  • Marsh G; Australian Animal Health Laboratory, CSIRO Health and Biosecurity, Geelong, VIC, Australia.
  • Young PR; Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Brisbane, QLD, Australia.
  • Agafonov AA; State Center for Virology and Biotechnology Vector, Koltsovo, Russian Federation.
  • Farmer JF; United Nations Medical Service, New York, NY 10017, USA.
  • Volchkov VE; Molecular Basis of Viral Pathogenicity, CIRI, INSERM, U1111-CNRS UMR5308, Université de Lyon, Université Claude Bernard Lyon 1, Ecole Normale Supérieure de Lyon, France.
  • Suhrbier A; QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
  • Khromykh AA; Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Brisbane, QLD, Australia.
Sci Rep ; 7: 41537, 2017 02 03.
Article en En | MEDLINE | ID: mdl-28155869
ABSTRACT
Herein we describe production of purified equine IgG obtained from horses immunized with plasmid DNA followed by boosting with Kunjin replicon virus-like particles both encoding a modified Ebola glycoprotein. Administration of the equine IgG over 5 days to cynomolgus macaques infected 24 hours previously with a lethal dose of Ebola virus suppressed viral loads by more than 5 logs and protected animals from mortality. Animals generated their own Ebola glycoprotein-specific IgG responses 9-15 days after infection, with circulating virus undetectable by day 15-17. Such equine IgG may find utility as a post-exposure prophylactic for Ebola infection and provides a low cost, scalable alternative to monoclonal antibodies, with extensive human safety data and WHO-standardized international manufacturing capability available in both high and low income countries.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoglobulina G / Fiebre Hemorrágica Ebola / Ebolavirus / Profilaxis Posexposición / Anticuerpos Antivirales / Antígenos Virales Límite: Animals Idioma: En Año: 2017 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoglobulina G / Fiebre Hemorrágica Ebola / Ebolavirus / Profilaxis Posexposición / Anticuerpos Antivirales / Antígenos Virales Límite: Animals Idioma: En Año: 2017 Tipo del documento: Article